Dmitry Balyasny’s Amicus Therapeutics FOLD Stock Holding History

Dmitry Balyasny’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-59,500	Closed	-$847K	–	3098
2025 Q4	$847K	Buy	+59,500	New	+$585K	﹤0.01%	2269
2024 Q4	–	Sell	-150,000	Closed	-$1.6M	–	2910
2024 Q3	$1.6M	Buy	+150,000	New	+$1.63M	﹤0.01%	1762

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Dmitry Balyasny's FOLD Position: Q2 2026 in Review

Dmitry Balyasny sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 3,827,513 shares — an estimated $55.3M sold.

Dmitry Balyasny first reported a position in FOLD in Q2 2013 and held it in 27 quarters. The position peaked at $73M in Q4 2025. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Dmitry Balyasny reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Dmitry Balyasny sold 3,827,513 Amicus Therapeutics shares in Q2 2026, an estimated $55.3M.
Dmitry Balyasny first reported a position in Amicus Therapeutics in Q2 2013 and held it in 27 quarters.
Dmitry Balyasny's Amicus Therapeutics position peaked at $73M in Q4 2025.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.